Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Succinate-semialdehyde dehydrogenase (SSADH) is an enzyme crucial for the degradation of γ-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system. The enzyme catalyzes the conversion of succinate semialdehyde to succinic acid, using NAD+ as a cofactor. This reaction is part of the GABA shunt, linking neurotransmitter metabolism to cellular energy production via the tricarboxylic acid (TCA) cycle. Deficiency or mutations in ALDH5A1 cause succinic semialdehyde dehydrogenase deficiency (also called SSADHD or gamma-hydroxybutyric aciduria), an autosomal recessive disorder characterized by neurological symptoms and elevated levels of GHB/GABA.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Succinate-semialdehyde dehydrogenase (SSADH).